Your shopping cart is currently empty

NLRP3-IN-17 is a potent, selective, and orally active inhibitor of the NLRP3 inflammasome with an IC50 of 7 nM, effectively inhibiting NLRP3-dependent IL-1β secretion in mice, making it valuable for chronic inflammatory disease research [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $140 | 5 days | 5 days |
| Description | NLRP3-IN-17 is a potent, selective, and orally active inhibitor of the NLRP3 inflammasome with an IC50 of 7 nM, effectively inhibiting NLRP3-dependent IL-1β secretion in mice, making it valuable for chronic inflammatory disease research [1]. |
| Targets&IC50 | NLRP3 inflammasome:7 nM |
| In vivo | NLRP3-IN-17 (compound 15) administered orally at 3 mg/kg demonstrated favorable pharmacokinetic (PK) data, with an area under the curve (AUC), half-life (t 1/2), and bioavailability (F%) of 4.2 μg.h/mL, 2.91 h, and 56%, respectively [1]. At a single oral dose of 10 mg/kg, it significantly inhibited NLRP3-dependent IL-1β secretion, reducing IL-1β levels by 44% in an acute in vivo LPS+ATP stimulation model in female C57BL/6 mice [1]. |
| Molecular Weight | 394.49 |
| Formula | C21H22N4O2S |
| Cas No. | 2254432-75-0 |
| Smiles | N#CN=S(=O)(NC(=O)NC=1C2=C(C=C3C1CCC3)CCC2)C4=CC=C(C=C4)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.